Security key
88338N206
TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD)
CUSIP: 88338N206
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 3,343,589
- Total 13F value
- $3,092,849
- Share change
- -185,156
- Put/Call ratio
- 18%
- SEC-reported price per share
- $0.92
- Number of holders
- 39
- Value change
- -$161,728
- Number of buys
- 11
- Number of sells
- 11
- Shares outstanding
- 11,627,985
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
39
Top holders
10
TXMD full security history
Ownership snapshot
Full 13F holder table
TherapeuticsMD, Inc. SEC filings
TherapeuticsMD, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Clearline Capital LP
Disclosed value leader
Rubric Capital Management LP
Comparable rows
15/15
Latest evidence
31 Dec 2024
13D/G
13F
3/4/5
Lead comparable stake: 5.5%
13D/G row: Clearline Capital LP
Showing 1-6 of 15 holder rows.
Quick read
Clearline Capital LP leads the comparable SEC ownership view at 5.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Clearline Capital LP's linked filing trail.
Comparable ownership
Top 5
Clearline Capital LP
5.5%
Rubric Capital Management LP
10%
Tejara Capital Ltd
3.4%
VANGUARD GROUP INC
3.3%
ADAR1 Capital Management, LLC
2.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Clearline Capital LP |
13D/G
13F
Company
|
5.5%
|
$705,096
635,222 shares
|
$0 | 31 Dec 2024 |
| Rubric Capital Management LP |
3/4/5
13F
Director, Other*, 10%+ Owner · Company
|
10%
from 13F
|
$6,718,950
2,946,908 shares
|
— | 15 Nov 2023 |
| Tejara Capital Ltd |
13F
Company
|
3.4%
|
$339,408
394,661 shares
|
— | 31 Dec 2024 |
| VANGUARD GROUP INC |
13F
Company
|
3.3%
|
$333,321
387,582 shares
|
— | 31 Dec 2024 |
| ADAR1 Capital Management, LLC |
13F
Company
|
2.3%
|
$232,338
270,160 shares
|
— | 31 Dec 2024 |
| CITADEL ADVISORS LLC |
13F
Company
|
1.3%
|
$125,404
145,802 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
39
Shares
3,343,589
Rows available
39
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
39
Q1 2025 holders
39
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|